盐酸缬更昔洛韦片疗效如何？

Valcyte is indicated for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis and the prevention of CMV infection in high-risk solid organ transplant patients. Valganciclovir hydrochloride tablets are sensitive to human viruses including human cytomegalovirus (HCMV), and valganciclovir hydrochloride tablets (Valcyte) are sensitive to herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV) and hepatitis B virus.

Valcyte hydrochloride tablets can inhibit viral activity mainly by inhibiting the synthesis of viral DNA: Valganciclovir hydrochloride tablets competitively inhibit viral DNA polymerase, preventing deoxyguanylate triphosphate from binding to DNA. The ganciclovir triphosphate in Valcyte hydrochloride tablets binds to viral DNA, terminating or limiting the elongation of the viral DNA chain. The IC50 of the antiviral effect of valganciclovir hydrochloride tablets on CMV in vitro ranges from 0.08μM (0.02ug/ml) to 14μM (3.5ug/ml).

How effective is Valganciclovir Hydrochloride Tablets?

The safety and efficacy of tablet treatment were verified in two different trials: The antiviral effect of valganciclovir hydrochloride tablets was clinically confirmed by treating AIDS patients with newly diagnosed retinitis (clinical study WV15376). The detection rate of CMV virus decreased from 46% (32/69) to 7% (4/55) after 4 weeks of treatment with valganciclovir hydrochloride tablets, and the U.S. Food and Drug Administration (FDA) approved the increased use of valganciclovir hydrochloride tablets in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease. The supplemental approval is based on data that longer-term prophylactic treatment with valganciclovir hydrochloride tablets reduced the incidence of CMV disease in high-risk adult kidney transplant patients from 36.8% (for patients who received 100 days of treatment) to 16.8% (for patients who received 200 days of treatment) one year after receiving a kidney transplant) (p <0.0001).1.2 The overall safety of valganciclovir hydrochloride tablets does not change when prophylaxis is extended in high-risk renal transplant patients.